CanBas Co., Ltd.
Stock Price Chart
2026/11/20 20:23 UpdatedPrice Trend
2026/11/20 20:23 UpdatedPrice & Trading Details
2026/11/20 20:23 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/11/01Financial Performance
2026/11/22 UpdatedNo financial data available
Latest IR Information
-
Notice Regarding Large-Scale Exercise of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Discloses large-scale exercise status of the 22nd stock acquisition rights during the month. Delivered shares: 1,485,000 shares; cumulative exercise ratio through November 19: 74.25%; unexercised rights reduced to 5,150 units. Monitor future movement of unexercised rights.
Read more -
Notice of Approval to Commence European Phase 3 Clinical Trial for CBP501
Received approval to commence the European Phase 3 clinical trial for CBP501. The trial targets third-line pancreatic cancer; the primary endpoint is overall survival. The trial is planned in about 50 sites across 8 countries. No earnings guidance for the...
Read more -
Notice on Massive Exercise of Series 22 Stock Acquisition Rights (with Exercise Price Adjustment Clause)
Due to large-scale exercises since the beginning of the month, the number of shares delivered totals 689 shares, representing an exercise ratio of 11.38% of the total issued shares. Unexercised units: 17,725. Period: 2026-11-02 to 2026-11-17.
Read more -
Notice of Completion of Payment for the Issuance of the 22nd Stock Acquisition Rights (with Exercise Price Adjustment Clause) and the 23rd and 24th Stock Acquisition Rights (with Option for Exercise Price Adjustment) by Third-Party Allotment
Announced completion of payment for the 22nd, 23rd, and 24th stock acquisition rights by third-party allotment. Disclosed details including allotment dates, number issued, total amount, number of potential shares, and adjustment conditions for each right.
Read more -
Notice of Completion of Payment for Newly Issued Shares as Restricted Stock Compensation
Payment for newly issued shares issued as restricted stock compensation has been completed. Allottees are 3 directors and 3 directors who are audit and supervisory committee members, totaling 57,000 shares at 719 yen per share, aggregate amount 40,983,000 yen.
Read more
Latest News (5 items)
Company Information
About
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.